

29<sup>th</sup> July, 2022

The Dy. General Manager (Listing Dept.)  
BSE Limited,  
Corporate Relationship Dept.,  
1<sup>st</sup> Floor, New Trading Ring,  
P. J. Towers, Dalal Street, Fort,  
Mumbai - 400 001  
**(BSE Scrip Code: 500420)**

The Manager – Listing Dept.,  
National Stock Exchange of India Ltd.,  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G. Block,  
Bandra - Kurla Complex, Bandra (E),  
Mumbai – 400 051  
**(NSE Scrip Code: TORNTPHARM)**

Dear Sir,


**Sub.: Presentation to analysts on unaudited Consolidated Financial Results for the quarter ended 30<sup>th</sup> June, 2022**

The presentation on unaudited Consolidated Financial Results for the quarter ended 30<sup>th</sup> June, 2022 to be made to analysts is enclosed for your records.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL  
VP (LEGAL) & COMPANY SECRETARY

Encl : A/a



## Q1 FY 2022-23

Revenues: Summary



# Revenue: Summary

Revenues (Rs cr)	Q1 FY23	Q1 FY22	Gr%
India	1,245	1,093	14%
United States	299	266	13%
Germany	214	260	-18%
Brazil	184	153	20%
Other countries	252	217	16%
Others	154	146	6%
<b>Total</b>	<b>2,347</b>	<b>2,134</b>	<b>10%</b>

